MOSCOW, April 15 — RIA Novosti. According to the world health organization (who), is now the world developed not less than 70 potential vaccines against coronavirus, and three of them are in the clinical trial.
Closest to completion is the vaccine developed by CanSino Biologics Inc. in Hong Kong and the Beijing Institute of biotechnology. It is already approved for human testing, is now in its second phase of clinical verification.
followed by vaccine two American biotech start — UPS- companies Moderna Inc. and Inovio Pharmaceuticals Inc., they had never launched such products. However, both companies missed obligatory in other cases, the stage of animal testing, usually lasting for years, and just moved to human trials.
participate In the development of a variety of organizations — from pharmaceutical giants and the tiny biotech companies to academic centers and nonprofit groups. However, the question is not only how to quickly complete the development. Given the pace of spread of the disease will need after approval of the vaccine to quickly produce it in large industrial scale. And this is the only large pharmaceutical companies with huge production capacity. Potential vaccines are in preclinical stages, already have manufacturers such as Pfizer Inc., Johnson & Johnson and Sanofi.
who recognizes that the pace of vaccine COVID-19 unprecedented. Typically, this is a costly, complex and lengthy process, requiring hundreds of millions of dollars of investment and years of testing to confirm that the vaccine is safe and effective.
Typically, the release of new vaccines to the market requires 10-15 years, but now companies are planning to reduce this period to a year and a half. This is because from the virus which has already claimed the lives of nearly 120 thousand people worldwide, yet there is no cure.
Despite the fact that the current pandemic is the third outbreak of the coronavirus in the twenty-first century (the first was SARS and MERS), are still no approved vaccines. Since it is unlikely that an infectious pathogen can be suppressed only with the help of containment measures, all hopes hinge on a new drug.
And yet, as history has shown HIV, there is no guarantee that the vaccine will generally be created. So researchers are working in different directions, not knowing as yet which of them will work.
Experts are concerned that the pass many of the required stages of testing potential vaccines increases the risk of their subsequent use. One of the risks they call the effect “immune amplification” — when a vaccine does not lead to the emergence of immunity, but rather weakens the body’s response to the virus.
To coordinate efforts in the development of vaccines against COVID-19 who has established an International platform for the registration of clinical trials, which task is to ensure that all involved in decision-making access to the full picture of scientific research.
the Latest data on the situation of COVID-19 in Russia and the world presented on the portal stopmanager.of the Russian Federation.
